Arm Holdings plc vs Novavax Inc — how do they compare? Arm Holdings plc trades at $274.32 (market cap $286.06B), while Novavax Inc trades at $7.97 (market cap $1.30B). The key difference: Arm Holdings plc is far larger — about 220× Novavax Inc's market cap, and Arm Holdings plc is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| ARM | NVAX | |
|---|---|---|
Market Cap | $286.06B | $1.30B |
Sector | Technology | Health |
52-Week High | $439.46 | $11.19 |
52-Week Low | $104.55 | $6.22 |
Enterprise Value | $282.64B | $879.40M |
Signals from Pluang's Aura AI — not financial advice
ARM stock trades at $282.57, down 1.43% over 24 hours, with a bullish technical outlook supported by moving averages and key support at $272. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.45 beating the $0.40 estimate. Revenue grew to $4.01B in 2025, with a net income margin of 20.25%, though valuation multiples remain elevated with a P/E of 273.32.
The outlook is positive due to AI-driven growth in licensing and royalties, with management targeting $25B revenue by FY31. However, risks include stretched valuation, smartphone market headwinds, and execution challenges. Analyst consensus is bullish with a $329.80 price target, suggesting 17% upside from current levels.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Arm Holdings designs the architecture for high-performance, energy-efficient processors used in nearly all smartphones and millions of other devices. Its intellectual property powers global computing from mobile to AI.
Read more on ARM →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →